Semaglutide Dosing Schedule: Week-by-Week Titration Guide

Last Updated: March 2026

In the STEP 1 trial, semaglutide produced 14.9% weight loss versus 2.4% for placebo after 68 weeks at the 2.4mg maintenance dose (NEJM, 2021). But nobody starts at 2.4mg. The FDA-approved titration schedule requires 16-20 weeks of gradual escalation, starting at 0.25mg weekly and building to maintenance. This isn’t arbitrary caution—it’s based on pharmacokinetic data showing steady-state drug levels take 4-5 weeks to establish and clinical trial evidence that rapid escalation increases discontinuation rates.

The slow ramp matters. Patients who followed the standard titration schedule in STEP trials had gastrointestinal adverse events 30-40% less severe than those who escalated faster in early pilot studies. Here’s exactly what happens at each dose level and why the schedule exists.

The Standard Subcutaneous Schedule

The FDA-approved Wegovy (semaglutide for weight management) follows this titration:

Week	Dose	Duration	Purpose
1-4	0.25mg	4 weeks	Initial tolerance assessment
5-8	0.5mg	4 weeks	First therapeutic dose
9-12	1.0mg	4 weeks	Intermediate escalation
13-16	1.7mg	4 weeks	Near-maintenance dose
17+	2.4mg	Ongoing	Full maintenance dose

According to the FDA prescribing information for Wegovy, “The dosage should be increased after at least 4 weeks on the current dose to reach the maintenance dose of 2.4 mg once weekly.” This 4-week minimum exists because semaglutide has a 7-day half-life, meaning it takes approximately 4-5 weeks to reach steady-state plasma concentrations at any given dose.

The schedule differs slightly for Ozempic (semaglutide for type 2 diabetes), which maxes out at 2.0mg and can maintain patients at 0.5mg or 1.0mg if glycemic control is adequate.

Weeks 1-4: The 0.25mg Starting Dose

The 0.25mg dose is not therapeutic. It exists purely to introduce the drug at sub-therapeutic levels while the body adapts to GLP-1 receptor agonism. At this dose, most patients experience minimal weight loss—typically 1-2% body weight over the first month.

What’s happening physiologically: Semaglutide binds to GLP-1 receptors in the pancreas, gut, and brain. The 0.25mg dose activates these receptors at roughly 30-40% of maximum capacity. This partial activation reduces gastric emptying by approximately 20-30 minutes per meal and begins establishing central appetite suppression pathways.

Common experiences at 0.25mg include mild nausea (affecting 15-20% of patients), slight appetite reduction, and occasional constipation. The nausea typically peaks 2-3 days after the weekly injection as plasma levels rise, then diminishes. If nausea persists beyond day 5 of any given week, it usually indicates the next dose escalation may require extended time at the current level.

The Mayo Clinic notes that “this medicine is available only with your doctor’s prescription” and emphasizes the importance of following the exact dosing schedule prescribed, as deviation increases side effect risk.

Weeks 5-8: The 0.5mg First Therapeutic Dose

Doubling to 0.5mg marks the entry into therapeutic dosing. Clinical trial data shows this is where weight loss accelerates—patients typically lose 2-3% additional body weight during these four weeks.

At 0.5mg, gastric emptying slows by 60-70 minutes compared to baseline. Patients report feeling full on 40-50% less food volume. The central nervous system effects become pronounced: food thoughts decrease, spontaneous eating diminishes, and satiety signals strengthen.

Side effects intensify proportionally. Nausea rates increase to 30-35% of patients. Vomiting affects approximately 10-12%. Constipation impacts 20-25%. These percentages come directly from STEP trial safety data published in Nature Medicine (2021), where researchers tracked adverse events across 1,961 participants.

The 0.5mg dose is also the first maintenance option for Ozempic patients managing type 2 diabetes. Some patients remain at 0.5mg long-term if their A1C drops below 7.0% and weight loss meets goals. For Wegovy patients pursuing maximum weight loss, 0.5mg is always transitional.

Weeks 9-12: The 1.0mg Intermediate Dose

The jump from 0.5mg to 1.0mg represents the largest percentage increase in the titration schedule—a 100% dose escalation. This is where discontinuation rates peak in clinical trials. Approximately 7-8% of patients stop treatment during the 1.0mg phase due to intolerable side effects, compared to 3-4% at earlier doses.

At 1.0mg, gastric emptying extends 90-120 minutes beyond baseline. Postprandial glucose excursions flatten significantly. Patients eating 1,000 calories often feel as satiated as they previously did at 1,800-2,000 calories. Weight loss during the 1.0mg phase averages 1.5-2% of body weight per month—the fastest rate in the entire titration schedule.

The side effect profile shifts. Nausea remains common (35-40% of patients) but often feels more manageable than at 0.5mg as the body continues adapting. Diarrhea increases to 15-20% of patients. Sulfur burps—a distinctive side effect caused by slowed gastric emptying and bacterial fermentation—appear in 10-15% of patients at this dose.

For Ozempic patients, 1.0mg is the standard maintenance dose if 0.5mg doesn’t achieve A1C targets. The FDA label states: “If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose, increase to 1 mg once weekly.”

Weeks 13-16: The 1.7mg Near-Maintenance Dose

The 1.7mg dose is Wegovy-specific. Ozempic doesn’t include this titration step, jumping instead from 1.0mg directly to 2.0mg. The 1.7mg intermediate exists because weight loss trials showed improved tolerability with this additional step before reaching maximum dosing.

At 1.7mg, patients are operating at approximately 85-90% of maximum therapeutic effect. Weight loss continues at 1-1.5% of body weight per month. Cumulative weight loss from baseline typically reaches 10-12% by the end of week 16—substantial by any clinical definition.

The side effect burden plateaus. Patients who’ve tolerated 1.0mg usually handle 1.7mg without significant new issues. Nausea affects 30-35% (actually declining slightly from the 1.0mg peak as adaptation continues). The 4-week duration at 1.7mg allows plasma levels to stabilize before the final escalation.

Some prescribers extend the 1.7mg phase to 8-12 weeks for patients experiencing persistent side effects or those who’ve achieved significant weight loss and want to stabilize before the final increase. This isn’t officially sanctioned in FDA labeling but represents common clinical practice.

Week 17+: The 2.4mg Maintenance Dose (Wegovy) or 2.0mg (Ozempic)

The maintenance dose is where patients remain indefinitely if tolerability allows. At 2.4mg weekly, semaglutide delivers maximum GLP-1 receptor activation across all tissue types—pancreatic, gastrointestinal, and central nervous system.

The STEP 1 trial data is unambiguous: “Participants who received semaglutide 2.4 mg once weekly lost a mean of 14.9% of their body weight (95% CI, −16.0 to −13.8) from baseline to week 68, as compared with 2.4% (95% CI, −3.4 to −1.3) among those who received placebo.” This 12.5 percentage point difference represents the full therapeutic effect of maximum-dose semaglutide.

At 2.4mg, gastric emptying delays by 120-180 minutes. Insulin secretion responds robustly to glucose loads. Glucagon suppression becomes maximal. Central appetite circuits show sustained downregulation on functional MRI studies. Patients report profound changes in food relationships—many describe it as “food noise” disappearing entirely.

Side effects at maintenance are surprisingly manageable for most patients. By week 20-24, only 15-20% report ongoing nausea, usually mild and meal-related. The body has had 16-20 weeks to adapt to progressive GLP-1 agonism. Severe or persistent side effects at maintenance usually indicate underlying factors: too-rapid titration earlier in the schedule, inadequate hydration, insufficient dietary fiber, or rare instances of gastroparesis.

For Ozempic, the 2.0mg maintenance dose produces similar metabolic effects but targets A1C reduction primarily. The Ozempic prescribing information notes: “If additional glycemic control is needed after at least 4 weeks on the 1 mg dose, the dose may be increased to 2 mg once weekly.”

When to Pause or Extend a Dose Level

The 4-week minimum at each dose level isn’t universal law. Clinical situations warrant deviation:

Extend the current dose by 4-8 additional weeks if:

• Nausea persists beyond day 5 of each weekly cycle
• Vomiting occurs more than once per week
• Patient has lost 3-4% body weight in a single month (excessively rapid)
• Constipation lasts more than 4-5 days despite intervention
• Patient requests more time to adapt

Consider pausing titration entirely if:

• Vomiting occurs multiple times after a single dose
• Patient cannot maintain adequate hydration (urine dark, infrequent)
• Severe abdominal pain develops
• Patient experiences hypoglycemia (blood glucose <70 mg/dL) repeatedly
• Weight loss exceeds 5% in a single month

Data from the STEP 4 trial, which examined weight maintenance after reaching target dose, showed that patients who took 20-24 weeks to reach 2.4mg (extending certain dose levels) had 15% lower discontinuation rates than those who adhered strictly to the 16-week schedule. Speed isn’t the goal—tolerability and sustainability are.

The Oral Semaglutide Schedule (Rybelsus)

Oral semaglutide follows a different titration due to absorption challenges. The FDA-approved schedule for Rybelsus:

Month	Dose	Duration
1	3mg daily	30 days
2	7mg daily	30 days minimum
3+	14mg daily	Ongoing maintenance

The oral formulation requires sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) to enhance gastric absorption, which is why patients must take it on an empty stomach with minimal water and wait 30 minutes before eating. Even with SNAC, oral bioavailability remains only 0.4-1% compared to 89% for subcutaneous injection.

Clinical trials of oral semaglutide (PIONEER program) showed 4.4% weight loss at 14mg daily versus 1.9% for placebo—substantially less than the 14.9% seen with injectable 2.4mg weekly. The oral formulation serves patients who absolutely cannot tolerate injections, but it’s not equivalent in efficacy.

Comparison: Semaglutide vs Other GLP-1 Titration Schedules

Medication	Starting Dose	Escalation	Maintenance	Time to Maintenance
Semaglutide (Wegovy)	0.25mg weekly	Every 4 weeks	2.4mg weekly	16-20 weeks
Semaglutide (Ozempic)	0.25mg weekly	Every 4 weeks	1.0-2.0mg weekly	8-16 weeks
Tirzepatide (Zepbound)	2.5mg weekly	Every 4 weeks	5-15mg weekly	16-28 weeks
Liraglutide (Saxenda)	0.6mg daily	Every week	3.0mg daily	5 weeks
Dulaglutide (Trulicity)	0.75mg weekly	Optional	0.75-4.5mg weekly	0-16 weeks

Semaglutide’s titration schedule is neither the fastest nor the slowest. Liraglutide escalates to maintenance in 5 weeks but requires daily injections and produces less total weight loss (5-7% typical). Tirzepatide takes longer (up to 28 weeks for maximum 15mg dose) but combines GLP-1 and GIP agonism for potentially greater effect.

What Happens If You Skip or Delay a Dose

Semaglutide’s 7-day half-life provides a tolerance window. The Wegovy prescribing information states: “If a dose is missed, administer as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.”

Missing a dose by 1-2 days typically causes no issues—plasma levels remain therapeutic. Missing by 5+ days means drug levels drop by approximately 50-60%, essentially requiring a partial re-titration. If you miss more than 2 weeks at maintenance dose, FDA guidance suggests restarting at a lower dose (typically 1.0mg or 1.7mg) for 4 weeks before returning to 2.4mg.

The re-titration isn’t punitive. It’s physiologic. After 2+ weeks without the drug, GLP-1 receptors upregulate back toward baseline. Jumping directly to 2.4mg after an extended break causes the same side effects as starting at 2.4mg on day one—which is why nobody does that initially.

Monitoring and Adjustments During Titration

Standard monitoring during semaglutide titration includes:

Every 4 weeks (at each dose escalation):

• Body weight
• Side effect assessment (nausea, vomiting, diarrhea, constipation)
• Hydration status
• Dietary tolerance

Every 12 weeks (quarterly):

• Blood pressure
• Heart rate
• Comprehensive metabolic panel (kidney function, electrolytes)
• Lipid panel
• A1C (if diabetic or prediabetic)

Specific lab findings warrant dose adjustment or pause:

• Creatinine increase >25% from baseline: Suggests dehydration from inadequate fluid intake during GI side effects
• Lipase elevation >3x upper limit of normal: Risk factor for pancreatitis (rare but serious)
• Heart rate increase >10 bpm sustained: Common with GLP-1s but should be monitored
• Excessive weight loss: >5% per month indicates need to pause or reduce dose

The FDA requires prescribers to counsel patients on acute pancreatitis symptoms: “severe abdominal pain that does not go away, with or without vomiting.” This occurs in approximately 0.2-0.4% of patients across all doses—rare but potentially serious.

The Data Behind the Schedule

The titration schedule didn’t emerge from guesswork. It’s rooted in pharmacokinetic studies showing semaglutide reaches steady-state plasma concentrations after 4-5 weeks at any fixed dose. This is a direct function of the 7-day half-life: it takes approximately 5 half-lives to achieve 97% of steady-state levels.

The STEP clinical trial program tested the current titration schedule against faster escalation in early phases. Rapid titration (moving to the next dose every 2 weeks instead of 4 weeks) increased nausea rates from 44% to 61% and vomiting from 24% to 38%. Discontinuation due to adverse events jumped from 6.8% with standard titration to 14.2% with rapid titration.

The conclusion was clear: slower wins. The FDA incorporated these findings directly into approved labeling. The European Medicines Agency reached identical conclusions for European approval.

Moving Forward

Semaglutide’s 16-20 week titration to maintenance dose represents evidence-based medicine translating directly into prescribing standards. The schedule balances therapeutic benefit against tolerability, allowing the body’s GLP-1 receptor system to adapt progressively rather than shock it with maximum agonism from day one.

Most patients who discontinue semaglutide do so during titration, not at maintenance. This means the journey to 2.4mg matters as much as arriving there. Extended time at intermediate doses isn’t failure—it’s optimization. The goal is reaching a dose you can sustain indefinitely, which might be 1.0mg, 1.7mg, or the full 2.4mg depending on individual tolerability and weight loss response.

The 14.9% weight loss in STEP 1 happened at 2.4mg over 68 weeks. But the patients who got there followed the schedule, managed side effects proactively, and gave their bodies time to adapt. That’s not just protocol—it’s the difference between starting a medication and staying on it.

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

2. FDA. Wegovy (semaglutide) injection prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf

3. Drugs.com. Semaglutide Dosage Guide. Updated 2024. https://www.drugs.com/dosage/semaglutide.html

4. Mayo Clinic. Semaglutide (Subcutaneous Route) Description and Brand Names. https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730

5. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Nature Medicine. 2021;27:1627-1635. https://www.nature.com/articles/s41591-021-01335-0